Open AccessAngiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan
Author(s) -
Ольга Константиновна Викулова,
Marina Vladimirovna Shestakova
Publication year - 2009
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg33072
Subject(s) - losartan , medicine , ramipril , diabetes mellitus , myocardial infarction , cardiology , stroke (engine) , heart failure , telmisartan , angiotensin ii , blood pressure , endocrinology , mechanical engineering , engineering
Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE),such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another onein reducing the risk for CVE and death. The article summarizes the available data on ramipril in hypertensive patients of high cardiovascularrisk. The results of studies demonstrate strong and long-lasting antihypertensive effect of losartan. Moreover, losartan treatmentdecreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. Losartanshows both high efficacy and low adverse event rate.